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Background: The mutations in Plasmodium falciparum chloroquine resistance transporter (pfcrt), multidrug
resistance 1 (pfmdr1), dihydrofolate reductase (pfdhfr), dihydropteroate synthase (pfdhps) and ATPase (pfatp6) genes
were associated with anti-malaria drug resistance. The aim of this study was to investigate the prevalence of
polymorphisms in pfcrt, pfmdr1, pfdhfr, pfdhps and pfatp6 in Yunnan Province. Finger-prick blood samples were
collected from malaria-positive patients from Yunnan Province in 2009-2010. Single-nucleotide polymorphisms
(SNPs) in the resistance-related genes were analysed by various PCR-based methods.
Results: A total of 108 blood samples were collected. Although chloroquine has not been used to treat
falciparum malaria for nearly 30 years, 95.3% of the parasites still carried the pfcrt K76T mutation, whereas the
majority of isolates displayed the wild-type pfmdr1 N86 and D1246 sequences. The molecular level of
sulphadoxine–pyrimethamine resistance in P. falciparum was high. The most prevalent mutation was pfdhfr C59R
(95.9%), whereas the frequencies of the quadruple, triple and double mutants were 22.7% (N51I/C59R/S108N/I164L),
51.5% (N51I/C59R/S108N, N51I/C59R/I164L and C59R/S108N/ I164L) and 21.6% (N51I/ C59R, C59R/S108N and
C59R/I164L), respectively. A437G (n = 77) and K540E (n = 71) were the most prevalent mutations in pfdhps, and
52.7% of the samples were double mutants, among which A437G/K540E was the most common double mutation
(37/49). Quadruple mutants were found in 28.0% (26/93) of samples. A total of 8.6% of isolates (8/93) carried the
S436A/A437G/A581G triple mutation. No mutations were found in pfatp6 codons 623 or 769, but another two
mutations (N683K and R756K) were found in 4.6% (3/97) and 9.2% (6/97) of parasite isolates, respectively.
Conclusions: This study identified a high frequency of mutations in pfcrt, pfdhfr and pfdhps associated with CQ and
SP resistance in P. falciparum and no mutations linked to artemisinin resistance (pfatp6). Molecular epidemiology
should be included in routine surveillance protocols and used to provide complementary information to assess the
appropriateness of the current national anti-malarial drug policy.Background
Malaria is a major health problem in Southeast Asia,
where 1.3 billion people are at risk, and it causes ap-
proximately 120,000 deaths each year [1]. Despite signifi-
cant reductions in the overall malaria burden in the 20th
century, the disease still represents a significant public
health problem in China, especially in Yunnan Province
[2]. In 2010, the Ministry of Health in China launched* Correspondence: ipdtlh@sh163.net
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reproduction in any medium, provided the oran “action plan for malaria elimination”, with the goals
of eradicating local malaria cases in regions outside of
the Yunnan border area by the end of 2015 and eliminat-
ing malaria in the entire country by the end of 2020 [3].
Falciparum malaria is now found in only two provinces
in China, the Yunnan and Hainan Provinces [4]. Malaria
control measures have been actively implemented for
more than 30 years, and considerable success has been
achieved; there have been no local cases of falciparum
malaria in Hainan in the past two years [5]. However, the
malaria situation in Yunnan Province near the Myanmar
border remains serious. Yunnan Province is located in
southern China; it includes 131 counties and bordersLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The majority of malaria cases are concentrated in several
counties bordering Myanmar. The border with Myanmar
is 1,997 km long and approximately 98 million individ-
uals cross the border each year. Yunnan Province has an
estimated population of 42.36 million, with about 35.52
million people residing in malaria-endemic areas. From
2005 to 2011, malaria incidence decreased across the
province and the reported cases and deaths in the prov-
ince population have declined from 13,239 cases and 37
deaths in 2005 to 1,216 cases and zero deaths in 2011.
Of 2,643 reported cases, 28% were caused by Plasmodium
falciparum [6].
The first case of chloroquine (CQ) resistance in
P. falciparum was found in Yunnan Province in 1973,
and by the end of the 1970s, CQ resistance had spread
widely [7-9]. Subsequently, sulphadoxine–pyrimethamine
(SP) was introduced as the first-line drug for falciparum
malaria treatment. This antifolate combination seemed
to be an effective and reasonable alternative, but resist-
ance to SP also developed soon after its introduction in
China. Since 2001, the WHO has recommended the use
of artemisinin-based combination therapy in all areas
where P. falciparum is resistant to other anti-malarial
medicines to optimize therapeutic effectiveness and de-
lay the emergence of resistance. The WHO advocated a
complete ban on artemisinin monotherapy for uncom-
plicated malaria in 2006 [10]. The national drug policy
of China was updated in 2009, and the first-line drugs
currently used to treat falciparum malaria is artemisinin-
based combination therapy (ACT), which includes
dihydroartemisinin-piperaquine (DHA-PIP), artesunate +
amodiaquine, artemisinin-naphthoquine phosphate and
artemisinin-piperaquine [11].
Many factors have contributed to the development
and spread of drug resistance, including gene mutations
and drug pressure [12]. Molecular surveillance is a new
technique that has been implemented over the past
decades to provide complementary information to as-
sess the appropriateness of current policies based on
anti-malarial drugs [13]. Several molecular markers of
P. falciparum resistance have been identified. The K76T
allele in the CQ resistance transporter gene (pfcrt) is
associated with CQ and amodiaquine treatment failure
and could be used for the surveillance of clinical CQ re-
sistance [14-16]. The Y86 allele of multidrug resistance
gene 1 (pfmdr1) has been linked with CQ and amodia-
quine resistance [17]. The role of dihydrofolate reductase
(dhfr) and dihydropteroate synthase (dhps) mutations in
the mechanism of resistance to SP drugs has been well
described. Mutations associated with antifolate resist-
ance have been identified in codons 436, 437, 540, 581
and 613 in the pfdhps gene and codons 108, 51, 59, 140,
16 and 164 in the pfdhfr gene. The quintuple mutant ofpfdhfr (S108N, N51I and C59R) and pfdhps (A437G
and K540E) were associated with a high relative risk of
treatment failure, and this haplotype was suggested as a
relevant molecular marker for failure of SP treatment
in uncomplicated P. falciparum cases [18-21]. The
sarco/endoplasmic reticulum Ca2+-ATPase ortholog of
P. falciparum (pfatp6) was suggested to be involved in
the mechanism of parasite resistance to artemisinin
[22,23]. Specific point mutations in codons 769, 623 and
431 were associated with artemisinin resistance [24].
In recent decades, malaria drug resistance surveillance in
Yunnan Province has relied on in vitro and in vivo tests,
whereas molecular epidemiological studies of drug resist-
ance have only been conducted as limited studies [25,26]
and have not been used as a routine surveillance tool in
the national malaria programme. In this study, the preva-
lence of polymorphisms in pfcrt, pfmdr1, pfdhfr, pfdhps and
pfatp6 genes in blood samples obtained from P. falciparum-
infected patients in Yunnan Province were determined.
Methods
Sample collection and DNA extraction
The study was reviewed and approved by the ethics com-
mittee of the Chinese Centre for Disease Control and
Prevention (China CDC). Blood samples were collected
from patients with uncomplicated P. falciparum infection
prior to drug treatment. All of the patients came from
township hospitals in Tengchong and Yingjiang Coun-
ties in year 2009-2010. The initial diagnosis was made by
microscopic examination of Giemsa-stained thick blood
films or a rapid diagnostic test. For each sample, ap-
proximately 200 μl of finger-prick blood was spotted on
a piece of Whatman 3M 903 filter paper and air dried.
After the patients were confirmed as malaria, they would
get DHA-PIP. The dried filters were stored in individual
plastic bags at -20°C until DNA extraction. Parasite DNA
was extracted from the blood filters using a QIAamp
DNA mini kit (Qiagen, Valencia, CA, USA).
Genetic characterization of parasites
Nested PCR [14,20,27] was used to amplify fragments of
pfcrt, pfmdr1, pfdhfr, pfdhps and pfatp6. The amplified pro-
ducts were purified from an agarose gel and sequenced
with an automated DNA sequencer (ABI systems, Perkin-
Elmer, France). Sequence alignments and analysis were car-
ried out using Mega and BioEdit software. Amino acid
sequences were compared with wild-type sequences. The
sequences of the amplicons were aligned with 3D7 strain
published data from the NCBI database by BLAST analysis.
Results
Study sites
Yingjiang and Tengchong Counties, which have the
highest falciparum malaria incidence rates in China, are
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ively, in southwest Yunnan Province (Figure 1). In this
study, four township hospitals bordering with Myanmar
were selected to collect malaria samples. Of all of sam-
ples, 56 patients was local malaria cases and 52 patients
were contracted from Kachin State of Myanmar.
Prevalence of single-nucleotide polymorphisms in pfcrt
Codons 71, 72 and 76 were successfully amplified in 106
of the 108 samples analysed. The mutation in pfcrt
codon 76 was found in 95.3% (101/106) of parasite iso-
lates, and mutations in codons 71 and 72 were found in
3.0% (3/101) of parasite isolates. The mutant haplotype
CVIET in codons 72-76 was identified in 3% (3/101) of
samples and 5.0% (5/101) contained the wild-type haplo-
type CVMNK.
Prevalence of single-nucleotide polymorphisms in pfmdr1
All of the samples were genotyped for pfmdr1 at codons
86 and 1246. The majority of isolates displayed the wild-
type pfmdr1 N86 and D1246 alleles. A total of 5.6% (6/
108) of isolates carried the mutant allele Y86, and 94.4%
had the wild-type allele. No mutation in Y1246 was
found.Figure 1 The location of Yingjiang and Tengchong Counties relative tPrevalence in single-nucleotide polymorphisms
in pfdhfr and pfdhps
The single-nucleotide polymorphism (SNP) haplotype of
the pfdhfr gene at codons 16, 51, 59, 108, 140 and 164 is
linked with P. falciparum pyrimethamine resistance. The
pfdhfr gene was successfully amplified in 97 samples,
four of which contained amino acid substitutions com-
pared with the wild-type sequence. The most prevalent
mutation was C59R (95.9%). There were no mutations
in codons 16 or 140. A total of 38 of 97 isolates carried
the wild-type N51 allele, while 55 carried the mutant I51
allele, and four had mixed alleles; 93 and 58 of 97 iso-
lates had mutant R59 and N108, respectively. A total of
18.6% (18/97) of isolates carried the wild-type I164,
while 75.3% (73/97) carried mutant L164, and 6 had
mixed alleles (Table 1).
More than half (51.5%) of the isolates had triple muta-
tions, including N51I/C59R/S108N (n = 35), N51I/C59R/
I164L (n = 20) and C59R/S108N/ I164L (n = 21). The
double mutants included N51I/ C59R (n = 5), C59R/
S108N (n = 6) and C59R/I164L (n = 10). A total of 22.7%
(22/97) carried quadruple mutations at codons N51I/
C59R/S108N/I164L, and only one isolate had a single
mutation at codon R59 (Figure 2).o neighbouring countries.
Table 1 Prevalence of haplotypes of SNPs in pfdhfr and
pfdhps in P. falciparum isolates from Yunnan Province
Gene Haplotypes N %









G437/ E540 37 38.1
pfdhfr/pfdhps I51/R59/N108+ G437/ E540 19 19.8
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pfdhps polymorphisms at codons 436, 437, 540, 581 and
613, which are associated with P. falciparum sulphadox-
ine resistance. The A437G (n = 77) and K540E (n = 71)
mutants were most prevalent in pfdhps. A total of 52
isolates carried the wild-type S436 allele, and 41 had the
mutant A436 allele. A total of 53.8% of samples carried
the wild-type A581 allele, while 44.1% (50/93) had the
G581 allele, and 2 isolates had mixed alleles (Table 1).
Double pfdhps mutants were found in 52.7% of isolates
(49/93). The most prevalent double mutant was A437G/
K540E (N=37), followed by S436A/A437G (n=4), S436A//
K540E (n=1), A437G/A581G (n=3) and K540E/A581G
(n = 4). Quadruple mutants were found in 28.0% (26/93)
of samples. A total of 8.6% (8/93) of samples were
S436A/A437G/A581G triple mutants, and 10 isolatesFigure 2 Frequency of pfdhfr haplotypes in samples from Yingjiang C
C59R, S108N and I164L of the pfdhfr gene is linked with Plasmodium falcipahad a single mutation at A436 (n = 4), E540 (n = 5) or
G581 (n = 1) (Figure 3).
Besides, the quintuple mutant of pfdhfr (S108N,
N51I and C59R) and pfdhps (A437G and K540E) were
shown in Table 1, which werewere associated with a
high relative risk of treatment failure, and this haplo-
type was suggested as a relevant molecular marker for
SP resistance.
Prevalence of single-nucleotide polymorphisms in pfatp6
No mutations in pfatp6 codons 623 or 769 were found,
but another two mutations (N683K and R756K) were
found in 4.6% (3/97) and 9.2% (6/97) of parasite isolates,
respectively.
Discussion
Yunnan Province has experienced considerable eco-
nomic development in the last 10 years; based on the
appearance of villages at present compared with 1999-
2000, the standard of living, even in rural areas, has
improved considerably. During this time, there has also
been a significant decline in the number of malaria cases
reported. However, suspected artemisinin resistance oc-
curring in Mekong areas and difficulties for mobile
population management in bordering areas will presents
a challenge for eliminating malaria in the entire country
by the end of 2020.
Pfcrt has been demonstrated to be a major determin-
ant of CQ resistance in P. falciparum, and the K76T
mutation has been widely used as a reliable marker for
CQ resistance in epidemiological studies [28-30]. Since
CQ resistance was first found in China, it has spread
widely, prompting the use of ACT to treat falciparum
malaria. According to a longitudinal survey conductedounty. The frequency of the constructed haplotypes of SNPs in N51I,
rum pyrimethamine resistance (n = 97).
Figure 3 Frequency of pfdhps haplotypes in samples from Yingjiang County. The frequency of the constructed SNP haplotypes in the
pfdhps gene at S436A, A437G, K540E and A581G is linked with Plasmodium falciparum sulphadoxine resistance (n = 93).
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for falciparum malaria, the resistance of P. falciparum to
CQ declined progressively after CQ use was stopped or
reduced, as determined by in vitro tests [9,31]. However,
the result of this study showed a high frequency of the
K76T mutation of pfcrt, which is consistent with other
studies conducted in China [25,26]. Several theories have
been proposed for the persistence of the K76T mutation.
The most important proposed reason was the wide use
of CQ to treat Plasmodium vivax. Although CQ has not
been used to treat P. falciparum in China for more than
30 years, the stable and high prevalence of CQ resistance
may be caused by the continued use of CQ as a first-line
drug for the treatment of P. vivax. This factor may be
responsible for the slow decline of P. falciparum CQ re-
sistance in Southeast Asia, especially in the Mekong
sub-region [32,33].
Compared with the high prevalence of the pfcrt muta-
tion, few samples had mutations in codon 86 and no
mutations were found in codon 1246 of pfmdr1. This re-
sult was consistent with the findings of other researchers
[25,26,34,35]. The Y1246 allele of pfmdr1 was not related
with CQ resistance, which was not consistent with the
results in Africa [36]. However, the prevalence of the
mutation at Y86 was still high in parasite isolates from
some countries in Southeast Asia. Pfmdr1 mutations dif-
ferentially affected the CQ responses in CQ resistance
parasites and their activities depending on the pfcrt
haplotype to which they were associated [37,38], and
pfmdr1 gene copy number amplifications and most of
the pfmdr1 gene amplifications in field samples harbors
an asparagine at 86 amino acid position of pfmdr1 gene
[39,40]. Mefloquine has never been used in Yunnan
Province, which would also be related to the low preva-
lence of mutation of the pfmdr1 gene.The role of pfdhfr and pfdhps mutations in the mech-
anism of resistance to SP drugs has been well described.
Pyrimethamine was used for the radical treatment of
P. vivax in combination with primaquine 40 years ago.
Additionally, pyrimethamine added to salt was used for
prophylaxis in the 1980s [30]. Pyrimethamine plus pri-
maquine has always been recommended as prophylactic
medicine for specific populations in China [6]. This
study found that the prevalence of quadruple, triple and
double mutant P. falciparum at the China-Myanmar
border was still high. The finding of this study was similar
to that in northeast Myanmar, Thailand and Cambodia,
where highly mutated pfdhfr and pfdhps genotypes were
also common [41,42]. SP monotherapy was used for a
short time after CQ resistance had spread widely, and
artemisinin drugs were subsequently introduced and
gradually became the standard of malaria therapy. How-
ever, it is unclear how to explain the discrepancy between
the absence of SP pressure and the high prevalence of
the pfdhfr triple mutants and pfdhps double mutants. it
could be speculated that SP drugs were frequently used
in bordering countries of the Mekong sub-region for
long periods, and the frequent population migration
across borders ensured high regional gene flow, includ-
ing these drug resistance genes.
The mechanism of action of artemisinin remains con-
troversial.In vivo artemisinin resistance has been pro-
posed [43] and identified by the presence of significantly
decreased parasite reduction rates, manifested clinically
by markedly longer parasite clearance times from the
body [44-47]. The molecular basis for this phenomenon
is uncertain. One of the proposed mechanisms is the
interaction with the sarcoplasmic reticulum Ca2+ ATPase6.
The analysis of naturally occurring polymorphisms in
pfatp6 in field isolates suggested that a polymorphism at
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bility of these isolates to artemether in vitro [23]. Like
other investigators, there were no polymorphisms in
codons 263 and 769, described as the key amino acids
for the interaction between pfatp6 and artemisinin [24].
However, two mutations (N683K and R756K) were iden-
tified in parasite isolates in this study, which has been
found in Zanzibar and Tanzania [48], and no mutation
in position 683 has been published previously [49].
Mutations observed in this study and previous studies
[50,51] could be indirectly implicated in artemisinin sus-
ceptibility. Although artemisinin resistance in western
Cambodia seems to be a heritable genetic trait, none of
the candidate genes suggested by earlier studies confer
artemisinin resistance. A genome-wide approach using
whole genome sequencing and transcriptome studies to
identify the molecular basis of artemisinin resistance has
been suggested [52].Conclusion
This study reports the high frequency of mutations in
pfcrt, pfdhfr and pfdhps, which are associated with CQ
and SP resistance in P. falciparum, but no mutation
linked with artemisinin resistance in pfatp6. Although,
molecular marker of artemisinin resistance has not been
identified yet, this result of other in vivo tests in Yunnan
Province (unpublished data) indicates that current ACT
drugs for P. falciparum treatment are still effective. In
addition, molecular epidemiology should be part of rou-
tine surveillance to produce complementary information
to assess the appropriateness of the current national
anti-malarial drug policy.
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